Daily Cosmetic Research Analysis
Analyzed 16 papers and selected 3 impactful papers.
Summary
A three-fraction accelerated partial breast irradiation regimen maintained excellent cosmesis with very low local recurrence at four years. Polymer- and size-dependent endocrine modulation by nanoplastics was demonstrated using OECD-aligned in vitro assays, with mixture effects and no steroidogenesis disruption. A flavonoid, Corylin, extended female mouse lifespan via RAGA–mTOR suppression and sex-dependent SIRT3 restoration, highlighting a mechanistic geroscience avenue.
Research Themes
- Ultra-hypofractionated breast radiotherapy with preserved cosmesis
- Endocrine activity of consumer-relevant nanoplastics and mixture effects
- Mechanistic geroscience targeting mTOR/SIRT3 with sex-specific efficacy
Selected Articles
1. Corylin promotes healthy aging via RAGA-mTOR suppression and sex-dependent activation of SIRT3.
Mid-life Corylin improved metabolic, muscular, and functional phenotypes and extended median lifespan in female mice but not males. Multi-omics linked benefits to suppression of mTOR via direct interaction with RAGA and restoration of SIRT3 and energy metabolic programs in females.
Impact: Provides mechanistic evidence that a botanical flavonoid engages RAGA–mTOR and SIRT3 to promote healthy aging with sex-specific efficacy. Offers a tractable target pathway for geroscience interventions.
Clinical Implications: Identifies Corylin and RAGA–mTOR/SIRT3 as candidate axes for geroprotective interventions; emphasizes the need for sex-specific translation and human safety/pharmacokinetic studies before clinical trials.
Key Findings
- Corylin extended median lifespan by 11.9% in female mice and increased 125-week survival by 33%, with no comparable benefit in males.
- Integrated multi-omics across tissues linked Corylin to suppression of mTOR signaling via direct interaction with RAGA.
- Corylin restored SIRT3 protein levels and energy-associated metabolic programs in females.
Methodological Strengths
- Comprehensive multi-omics integration across multiple tissues with in vivo functional readouts.
- Mechanistic target engagement evidence linking Corylin to RAGA–mTOR and sex-stratified analyses.
Limitations
- Preclinical mouse data; human safety, dosing, and efficacy remain untested.
- Sex-specific benefits were observed, limiting generalizability and necessitating tailored translation.
Future Directions: Define human pharmacokinetics/safety, validate target engagement in humans, and test efficacy in sex-stratified early-phase trials; explore structure-activity relationships and combination strategies with mTOR/SIRT modulators.
Aging is accompanied by progressive physiological decline and an increased risk of chronic disease, motivating the search for interventions that promote healthy longevity. We found that mid-life administration of Corylin, a flavonoid derived from Psoralea corylifolia, improves metabolic function, muscle integrity, and physical performance in mice maintained on a standard diet. Corylin significantly extends median lifespan in female mice, with an 11.9% increase and a 33% higher survival rate at 125 weeks, whereas no comparable benefit is observed in males. Here, we show that integrated multi-omics analyses across multiple tissues reveal coordinated age-associated molecular changes modulated by Corylin. These analyses link Corylin treatment to suppression of mechanistic target of rapamycin signaling, which is further supported by direct interaction between Corylin and Ras-related GTP-binding protein A. In addition, Corylin restores sirtuin 3 protein levels and energy-associated metabolic programs in female mice, providing mechanistic insight into sex-dependent longevity benefits.
2. Tri-APBI: Single Institution Phase I/II Prospective Clinical Trial of Three Fraction Accelerated Partial Breast Irradiation for Stage 0-I Breast Cancer.
In a prospective single-institution phase I/II study of 75 low-risk, hormone-sensitive, HER2-negative patients, three-fraction APBI delivered via EBRT or HDR over 2–3 days yielded a 2.6% ipsilateral recurrence at ~4 years with no grade ≥2 toxicity. Cosmetic outcomes remained good-to-excellent by subjective and quantitative pBRA measures, with minimal QoL impact.
Impact: Demonstrates feasibility of an ultra-short APBI schedule with excellent cosmetic preservation and low recurrence, potentially reducing patient burden without compromising control.
Clinical Implications: Tri-APBI may be considered for selected low-risk early breast cancer patients to shorten treatment while maintaining cosmesis and minimizing toxicity; multicenter randomized validation is warranted.
Key Findings
- Three-fraction APBI (EBRT 25.5 Gy/3fx or HDR 22.5 Gy/3fx) over 2–3 days achieved a 2.6% ipsilateral breast tumor recurrence at median 49 months with no grade ≥2 toxicity.
- Cosmesis remained good-to-excellent by both patient and physician ratings (≥91% at latest follow-up) and quantitative pBRA showed no worsening of asymmetry.
- Patient-reported QoL domains were largely unaffected, with isolated increases in breast symptom burden at 48–60 months and sexual functioning at 36 months.
Methodological Strengths
- Prospective phase I/II design with both EBRT and HDR modalities and median 49-month follow-up.
- Use of both subjective (patient/physician) and quantitative (pBRA) cosmesis assessments with defined PTV margins.
Limitations
- Single-institution, non-randomized study with modality selected by treating physicians, introducing potential selection bias.
- Limited sample size and follow-up beyond five years; comparative efficacy versus standard APBI/WBI remains to be established.
Future Directions: Conduct multicenter randomized trials comparing Tri-APBI with standard APBI/WBI, extend follow-up for late effects, and refine patient selection and modality choice (EBRT vs HDR).
PURPOSE: To report safety, feasibility, toxicity, cosmetic and quality-of-life (QoL) outcomes of a single institutional prospective phase I/II clinical trial evaluating a novel three-fraction accelerated partial breast irradiation (Tri-APBI) regimen. METHODS AND MATERIALS: From August 2018 to March 2021, 75 patients with low-risk hormone sensitive, HER2 negative breast cancer were enrolled on Tri-APBI, delivered with high dose rate (HDR) brachytherapy (22.5 Gy in 3 fractions) or external beam radiation therapy (EBRT) (25.5 Gy in 3 fractions) over 2-3 days. Modality was chosen by the treating physician. Planning target volume (PTV) for all patients was created using a 1-cm expansion of breast tissue around the surgical bed limited by 0.5 cm from the skin surface. RESULTS: Stage I disease was present in 79%, while the remainder had DCIS. Tri-APBI was delivered with EBRT in 45 patients (60%) and HDR in 30 (40%). At a median follow-up of 49 months (IQR 42 - 55 months), there were two ipsilateral breast tumor recurrences (IBTR), cumulatively 2.6%, both successfully salvaged. There were no axillary or distant recurrences. There was no CTCAEv4.0 grade 2+ toxicity observed. Good-to-excellent pretreatment cosmesis was present in 94% and 99% by patient and physician rating, respectively, and in 91% and 98% at latest follow-up. Quantitative cosmesis assessed by percentage of breast retraction assessment (pBRA) showed that breast asymmetry did not worsen compared to pre-treatment, with a baseline mean pBRA of 8.1% (CI 4.1 - 12) and a 24-month mean pBRA of 6.1% (CI 4.0 - 8.1). Tri-APBI did not negatively impact most domains of patient-reported quality of life, except breast symptom burden at 48 and 60 months and sexual functioning at 36 months only. CONCLUSIONS: Tri-APBI as delivered with EBRT or HDR in this trial was feasible and well-tolerated, with low IBTR rates at 4 years and minimal impact on patient-reported quality of life, qualitative, and quantitative cosmesis. Further follow-up is needed to evaluate long-term oncologic efficacy.
3. Surface-driven endocrine activity of nanoplastics: polymer- and size-dependent estrogen and androgen receptors modulation without steroidogenesis perturbation.
Across four polymers and size-resolved nanoplastics, PE and PP nanoparticles modulated ER/AR signaling without cytotoxicity, while PS/PET were inactive singly; mixtures showed potentiation. H295R steroidogenesis was not altered, indicating a receptor-proximal, surface-driven mode of action.
Impact: Establishes polymer- and size-specific endocrine receptor activity of nanoplastics using OECD TGs and highlights mixture effects, informing exposure monitoring and risk assessment beyond polystyrene models.
Clinical Implications: Guides prioritization of polymers/sizes (notably PE/PP and mixtures) in exposure monitoring and regulatory safety evaluation for consumer and cosmetic-related nanoplastics.
Key Findings
- PE (350 nm) and PP (180 nm; also 50 nm for AR) modulated ER (agonism) and AR (antagonism) without cytotoxicity across 0.1–10 mg/L; PS and PET were inactive when tested individually.
- Mixtures elicited ER/AR responses even when constituent singles were inactive, demonstrating mixture-dependent potentiation.
- H295R steroidogenesis assay did not meet the OECD decision rule for altered steroidogenesis; receptor-level effects occurred without changes in estradiol/testosterone.
Methodological Strengths
- OECD-aligned TG 455/456/458 across multiple cell models with polymer- and size-resolved materials and matched mixtures.
- Systematic assessment without cytotoxicity confounding, enabling receptor-specific interpretation.
Limitations
- In vitro findings without in vivo confirmation; real-world exposure levels and matrices were not modeled.
- Limited to four common polymers; broader material chemistries and surface modifications remain to be tested.
Future Directions: Quantify human-relevant exposure and biomonitoring, assess in vivo endocrine endpoints, and develop mixture modeling frameworks; dissect surface chemistry determinants of receptor interactions.
Growing production and use of plastics have led to significant environmental pollution including the formation and accumulation of plastic nanoparticles (PNPs). Due to their small size, PNPs easily enter the human food chain; however, humans are also exposed to plastics through other consumer pathways, such as the use of cosmetic products. Despite considerable efforts to investigate the potential adverse effects of plastics, their impact on human health is not yet fully understood. In particular, endocrine disruption has emerged as a potential mechanism underlying reported reproductive and hormonal effects of micro- and nanoplastics. We applied an OECD-aligned in vitro test guidelines (TGs) to a factorial panel of eight PNPs spanning four common polymers (polystyrene (PS), polyethylene (PE), polypropylene (PP), polyethylene terephthalate (PET)) with size-resolved materials and polymer-matched mixtures. Thus, estrogen receptor a (ERα) transactivation (TG 455), androgen receptor (AR) transactivation (TG 458, antagonist mode), and H295R steroidogenesis (TG 456) assays were performed using HeLa-9903, AR-EcoScreen GR KO M1, and NCI-H295R cell models, respectively. Across 0.1-10 mg L⁻¹, no cytotoxicity was observed. PENPs (350 nm) and PPNPs (180 nm) acted as ER agonists, whereas PPNPs (50 and 180 nm) and PENPs (350 nm) antagonized AR; PSNPs and PETNPs showed no activity when tested individually. Notably, several mixtures elicited ER and AR responses even when constituent singles were inactive, indicating mixture-dependent potentiation. In contrast, the H295R assay did not meet the OECD decision rule for altered steroidogenesis: sporadic shifts in pathway intermediates did not propagate to estradiol or testosterone. Altogether, the data support a surface- and polymer-dependent, receptor-proximal mode of action for PNPs and highlight mixture effects as a critical, underappreciated driver. These results move endocrine hazard evaluation beyond polystyrene surrogates and provide decision-useful guidance on which polymers/sizes and mixture contexts merit priority in exposure monitoring and risk assessment.